open access

Vol 11, Supp. H (2015)
Case report
Published online: 2015-12-18
Get Citation

Prolonged response to treatment with ipilimumab in a patient with a diagnosis of disseminated malignant melanoma

Ewa Chmielowska

open access

Vol 11, Supp. H (2015)
CASE REPORT
Published online: 2015-12-18

Abstract

Ipilimumab is a first immune checkpoints inhibitors. Ipilimumab is a standard therapy for advanced melanoma. In Poland the reimbursment of this drug includes only melanoma of the skin in the second line systemic therapy. We describe a case of a middle-age woman with a diagnosis of malignant disseminated melanoma (primary diagnosis was adenocarcinoma) in which the use of ipilimumab induction in second line treatment resulted long-term clinical benefit — 30 months free of the disease symptoms.

Abstract

Ipilimumab is a first immune checkpoints inhibitors. Ipilimumab is a standard therapy for advanced melanoma. In Poland the reimbursment of this drug includes only melanoma of the skin in the second line systemic therapy. We describe a case of a middle-age woman with a diagnosis of malignant disseminated melanoma (primary diagnosis was adenocarcinoma) in which the use of ipilimumab induction in second line treatment resulted long-term clinical benefit — 30 months free of the disease symptoms.

Get Citation

Keywords

malignant melanoma, dissemination, ipilimumab

About this article
Title

Prolonged response to treatment with ipilimumab in a patient with a diagnosis of disseminated malignant melanoma

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. H (2015)

Article type

Case report

Pages

7-10

Published online

2015-12-18

Keywords

malignant melanoma
dissemination
ipilimumab

Authors

Ewa Chmielowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl